Homologous recombination repair deficiency (HRD): From biology to clinical exploitation
- PMID: 33486842
- DOI: 10.1002/gcc.22939
Homologous recombination repair deficiency (HRD): From biology to clinical exploitation
Keywords: PARP inhibitor; breast cancer; homologous recombination repair; ovarian cancer; pancreatic cancer; prostate cancer.
References
REFERENCES
-
- Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509-2520. https://doi.org/10.1056/NEJMoa1500596.
-
- Heeke AL, Pishvaian MJ, Lynce F, et al. Prevalence of homologous recombination-related gene mutations across multiple cancer types. JCO Precis Oncol. 2018;2:1-13. https://doi.org/10.1200/PO.17.00286.
-
- Chang HHY, Pannunzio NR, Adachi N, Lieber MR. Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol. 2017;18(8):495-506. https://doi.org/10.1038/nrm.2017.48.
-
- Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355(6330):1152-1158. https://doi.org/10.1126/science.aam7344.
-
- McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109-8115. https://doi.org/10.1158/0008-5472.CAN-06-0140.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
